Sorafenib in Treating Patients With Locally Advanced or Metastatic Liver Cancer and Cirrhosis

Stopped early · Phase 1

Conditions studied: Liver Cancer

In brief

RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of sorafenib in treating patients with locally advanced or metastatic liver cancer and cirrhosis.

Key facts

Study ID

NCT00767468

Run by

UNC Lineberger Comprehensive Cancer Center

People needed

6

Starts

2008-10-01

Expected to finish

2010-11-01

Last updated by the study team

2012-05-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill — Chapel Hill, North Carolina, United States
• Duke Comprehensive Cancer Center — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.